Summary
A phase II single-blind, randomized, placebo-controlled trial to study the efficacy and safety of Study Drug administered as adjunctive treatment to patients with acquired thrombotic thrombocytopenic purpura.
Register to download
PRA Successfully Rescues Phase II Hematology Study
You may also be interested in:
Case Study
Innovative Technology Solution for a 15 Year Rare Disease Gene Therapy Registry
A Top 10 pharmaceutical client required a mobile technology solution to collect safety and effectiveness data on a groundbreaking treatment for an…
View Resource
Infographic
The Fight Against Rare Diseases
Collectively, rare diseases represent a large medical challenge. While most have no cure, the appropriate treatment can greatly improve quality of…
View Resource
resource
The Future of Clinical Trials: Connected and Virtual Approaches for Rare Diseases
Scott Schliebner, Senior Vice President, Center for Rare Diseases at PRA Health Sciences talks about how amore patient-centred approach is needed to…
View Resource
View all related content and resources for Rare Disease
Explore Insights